Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)

Metastatic cancer pancreas has been a challenge for oncologists over the years. It is a disease of limited survival and a very poor response to treatment. The median overall survival at five years is expected to be between 4-6% only. Adenocarcinoma is the most common type of pancreatic cancer. It is the tenth most common adult solid malignancy. Most of the new therapeutic modalities has proven to be non-beneficial in this disease including targeted and immunotherapy.

For many years, the first line of treatment for pancreatic cancer was gemcitabine either alone or in combinations. Recently, FOLFIRINOX has become the standard of care due to its overall survival benefit. However, it is a small benefit on the expense of great toxicity.

Patients with metastatic cancer pancreas are recruited to receive the test regimen. Baseline evaluation will be done either by CT scan or PET/CT. re-evaluation will be repeated after 3 months of treatment and at end of 6 months

Inclusion criteria

• Histopathological evidence of adenocarcinoma of the pancreas
• Radiological proof of metastatic disease as defined by AJCC

Exclusion criteria

• patients with poor performance status (ECOG 4)
• patients with organ dysfunction defined as: creatinine more than 1.6 mg/dl or bilirubin more than 3 mg/dl
• patients with end stage renal disease who are under regular dialysis
• other histologies of pancreatic cancer
• irresectable pancreatic cancer if not metatatic